Version history

{
  "session_id": "sess_SDA-2026-04-15-gap-debate-20260410-112400-454036f1_20260416-035530",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"Temporal Clonal Replacement from Protective TRM to Pathogenic Effector Clones\",\n      \"mechanism\": \"CD8+ T cells shift from neuroprotective tissue-resident memory (CD69+CD103+) to cytotoxic terminally-differentiated effectors (KLRG1+PD-1-) via CXCR3-mediated recruitment during neurodegeneration progression.\",\n      \"target_gene\": \"CXCR3\",\n      \"confidence_score\": 0.7,\n      \"novelty_score\": 0.6,\n      \"feasibility_score\": 0.5,\n      \"impact_score\": 0.8,\n      \"composite_score\": 0.68,\n      \"testable_prediction\": \"CXCR3 blockade in aged 5xFAD mice will preserve TRM cells while blocking pathogenic effector infiltration, reducing neuron loss without impairing viral surveillance.\",\n      \"skeptic_concern\": \"Mechanistic driver of TRM-to-effector transition remains undefined; circularity risk if aging causes replacement and replacement causes pathology.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"Chronic Antigen Exposure Driving Terminal Differentiation\",\n      \"mechanism\": \"Accumulation of misfolded proteins (Aβ/α-synuclein) or latent viral antigens drives persistent CD8+ T cell stimulation through MHC-I presentation, resulting in progressive terminal differentiation and loss of protective function.\",\n      \"target_gene\": \"MHC-I (B2M)\",\n      \"confidence_score\": 0.55,\n      \"novelty_score\": 0.65,\n      \"feasibility_score\": 0.45,\n      \"impact_score\": 0.7,\n      \"composite_score\": 0.60,\n      \"testable_prediction\": \"Single-cell TCR sequencing of CD8+ T cells from aged brains will show antigen-expanded clones with exhausted/effector phenotypes that correlate with local antigen burden.\",\n      \"skeptic_concern\": \"Specific antigenic triggers remain unidentified; distinguishing pathogenic from bystander activation is technically challenging.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"Microenvironmental IL-15/IL-12 Dysregulation Favoring Effector Commitment\",\n      \"mechanism\": \"Aging brain microenvironment exhibits elevated IL-15 and IL-12 levels that drive CD8+ T cell differentiation toward KLRG1+ effectors while undermining TRM maintenance, creating a niche shift favoring cytotoxicity.\",\n      \"target_gene\": \"IL15\",\n      \"confidence_score\": 0.5,\n      \"novelty_score\": 0.55,\n      \"feasibility_score\": 0.5,\n      \"impact_score\": 0.65,\n      \"composite_score\": 0.55,\n      \"testable_prediction\": \"Conditional IL-15 deletion in brain endothelial cells or blockade with IL-15R-Fc in aged mice will maintain CD69+CD103+ TRM populations and reduce cytotoxic CD8+ infiltrates.\",\n      \"skeptic_concern\": \"Cytokine redundancy and systemic effects of IL-15 inhibition may limit specificity; optimal temporal window for intervention unclear.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"CD8+ T cells serve both protective (immune surveillance) and pathogenic (cytotoxic) roles in neurodegeneration depending on activation state\",\n    \"CXCR3-mediated recruitment pathway represents the most actionable therapeutic target for selective modulation\",\n    \"A 'one cell type, two functions' model better explains contradictory literature than absolute protection or harm\"\n  ],\n  \"dissent_points\": [\n    \"Whether targeting infiltration (Hypothesis 1) or modulating existing cells (Hypotheses 2/3) is the superior therapeutic strategy remains unresolved\",\n    \"The relative contribution of brain-resident versus recruited CD8+ T cells to net outcomes is contested\"\n  ],\n  \"debate_summary\": \"The debate converged on a temporal-differentiation model where CD8+ TRM cells provide beneficial immune surveillance but are progressively replaced by recruited KLRG1+ effectors via CXCR3-mediated chemotaxis, reconciling protective and harmful roles. The strongest hypothesis (Hypothesis 1) offers a translationally actionable framework—immune normalization via CXCR3 blockade—though the Skeptic correctly identified that the mechanistic trigger for TRM-to-effector transition remains the critical missing link requiring resolution before rational therapy design.\"\n}",
  "tokens_used": "1010"
}